寶馨科技(002514.SZ):目前公司團隊的鈣鈦礦/異質結疊層電池實驗室自測效率已超30%
格隆匯7月20日丨寶馨科技(002514.SZ)在接受調研時表示,公司在連雲港500MW光伏組件產線已經投產,在懷遠投資的一期2GW異質結電池及組件項目將於年內投產。在內蒙古鄂托克旗投資的2GW切片、光伏異質結電池及組件項目以及安徽懷遠投資光伏異質結及組件二期中2GW項目正在推進中。
下一代產品鈣鈦礦/異質結疊層太陽能電池的開發也在加速推進,公司與張春福、朱衞東教授團隊以及大禹實業合資成立了西安寶馨光能科技有限公司,進行鈣鈦礦/異質結疊層電池研究和產業化推進,目前公司團隊的鈣鈦礦/異質結疊層電池實驗室自測效率已超30%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.